FZD6 Antibody (Center)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, E |
---|---|
Primary Accession | O60353 |
Other Accession | Q61089, NP_001158087.1, NP_003497.2 |
Reactivity | Human |
Predicted | Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 79292 Da |
Antigen Region | 493-520 aa |
Gene ID | 8323 |
---|---|
Other Names | Frizzled-6, Fz-6, hFz6, FZD6 |
Target/Specificity | This FZD6 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 493-520 amino acids from the Central region of human FZD6. |
Dilution | WB~~1:1000 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | FZD6 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | FZD6 |
---|---|
Function | Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Together with FZD3, is involved in the neural tube closure and plays a role in the regulation of the establishment of planar cell polarity (PCP), particularly in the orientation of asymmetric bundles of stereocilia on the apical faces of a subset of auditory and vestibular sensory cells located in the inner ear (By similarity). |
Cellular Location | Membrane {ECO:0000250|UniProtKB:Q61089}; Multi- pass membrane protein. Cell membrane {ECO:0000250|UniProtKB:Q61089}; Multi-pass membrane protein. Cell surface {ECO:0000250|UniProtKB:Q61089}. Apical cell membrane; Multi-pass membrane protein. Cytoplasmic vesicle membrane {ECO:0000250|UniProtKB:Q61089}; Multi-pass membrane protein. Endoplasmic reticulum membrane {ECO:0000250|UniProtKB:Q61089}; Multi-pass membrane protein. Note=Colocalizes with FZD3 at the apical face of cells (By similarity). Localizes to the endoplasmic reticulum membrane in the presence of LMBR1L (By similarity). {ECO:0000250|UniProtKB:Q61089} |
Tissue Location | Detected in adult heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, thymus, prostate, testis, ovary, small intestine and colon. In the fetus, expressed in brain, lung, liver and kidney |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene represents a member of the 'frizzled' gene family, which encode 7-transmembrane domain proteins that are receptors for Wnt signaling proteins. The protein encoded by this family member contains a signal peptide, a cysteine-rich domain in the N-terminal extracellular region, and seven transmembrane domains, but unlike other family members, this protein does not contain a C-terminal PDZ domain-binding motif. This protein functions as a negative regulator of the canonical Wnt/beta-catenin signaling cascade, thereby inhibiting the processes that trigger oncogenic transformation, cell proliferation, and inhibition of apoptosis. Alternative splicing results in multiple transcript variants.
References
Yerges, L.M., et al. J. Bone Miner. Res. 24(12):2039-2049(2009)
Kim, J.G., et al. J. Korean Med. Sci. 24(3):443-447(2009)
Miyakoshi, T., et al. Endocr. Pathol. 19(4):261-273(2008)
Sirchia, R., et al. Biol. Chem. 388(5):457-465(2007)
Lyons, J.P., et al. Exp. Cell Res. 298(2):369-387(2004)

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
